Details for Patent: 12,350,377

« Back to Dashboard

Which drugs does patent 12,350,377 protect, and when does it expire?

Patent 12,350,377 protects SYMPROIC and is included in one NDA.

This patent has nine patent family members in eight countries.

Summary for Patent: 12,350,377

Title:	Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
Abstract:	The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve.
Inventor(s):	Akira Mashimo, Shunji Ichio, Yoshinori Tamura, Kouichi Noguchi
Assignee:	Shionogi and Co Ltd
Application Number:	US17/156,892
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 12,350,377

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bdsi	SYMPROIC	naldemedine tosylate	TABLET;ORAL	208854-001	Mar 23, 2017		RX	Yes	Yes			Y

International Family Members for US Patent 12,350,377

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2873961
Denmark	2851075
European Patent Office	2851075
Spain	2903149